Patents by Inventor Yasunobu Yoshinaka
Yasunobu Yoshinaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11013722Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.Type: GrantFiled: February 11, 2019Date of Patent: May 25, 2021Assignee: KOWA COMPANY, LTD.Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
-
Publication number: 20190167645Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.Type: ApplicationFiled: February 11, 2019Publication date: June 6, 2019Applicant: KOWA COMPANY, LTD.Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
-
Patent number: 10258609Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.Type: GrantFiled: February 26, 2018Date of Patent: April 16, 2019Assignee: KOWA COMPANY, LTD.Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
-
Publication number: 20180185337Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.Type: ApplicationFiled: February 26, 2018Publication date: July 5, 2018Applicant: KOWA COMPANY, LTD.Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
-
Patent number: 9931321Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor (1).Type: GrantFiled: January 6, 2017Date of Patent: April 3, 2018Assignee: KOWA COMPANY, LTD.Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
-
Publication number: 20170112811Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.Type: ApplicationFiled: January 6, 2017Publication date: April 27, 2017Applicant: KOWA COMPANY, LTD.Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
-
Patent number: 9572798Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.Type: GrantFiled: September 27, 2013Date of Patent: February 21, 2017Assignee: KOWA COMPANY, LTD.Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
-
Publication number: 20150196538Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.Type: ApplicationFiled: September 27, 2013Publication date: July 16, 2015Applicant: KOWA COMPANY, LTD.Inventors: Toshiaki Takizawa, Yasunobu Yoshinaka
-
Publication number: 20140221390Abstract: Provided is a compound useful in the prevention and treatment of non-alcoholic steatohepatitis. A prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis which contains, as the active ingredient, 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, an acid-addition salt thereof, or a solvate of the same.Type: ApplicationFiled: January 23, 2014Publication date: August 7, 2014Applicant: KOWA COMPANY, LTD.Inventors: Haruki Shibata, Yasunobu Yoshinaka, Kimiyuki Shibuya
-
Publication number: 20130066075Abstract: Provided is a compound useful in the prevention and treatment of non-alcoholic steatohepatitis. A prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis which contains, as the active ingredient, 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, an acid-addition salt thereof, or a solvate of the same.Type: ApplicationFiled: May 18, 2011Publication date: March 14, 2013Applicant: KOWA COMPANY, LTD.Inventors: Haruki Shibata, Yasunobu Yoshinaka, Kimiyuki Shibuya
-
Publication number: 20110207742Abstract: There is to provide is an agent for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and/or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion comprising an effective amount of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-p yridyl]acetamide (hereinafter, referred to as compound 1), its pharmaceutically acceptable salt or a hydrate thereof and Pitavastatin, and a pharmaceutically acceptable carrier, wherein the agent is intended to be simultaneously administered, or separately administered with interval of time to a patient in need thereof There is also to provide a method for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and/or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion, comprising simultaneously administering, or separately administering with interval of time an effective amount of the compound 1, its pharmaceutically acceptable salt or a hydrate thereof and an effecType: ApplicationFiled: April 28, 2011Publication date: August 25, 2011Applicant: KOWA CO., LTD.Inventors: Hideyuki Kobayashi, Yasunobu Yoshinaka, Kimiyuki Shibuya
-
Patent number: 7973053Abstract: The present invention provides a medicament exhibiting an excellent nerve cell death inhibitory action. The present invention relates to a nerve cell death inhibitor comprising a pitavastatin and donepezil or a salt thereof in combination.Type: GrantFiled: October 2, 2008Date of Patent: July 5, 2011Assignee: Kowa Company, Ltd.Inventors: Fumiyasu Sato, Yasunobu Yoshinaka, Taro Aoki
-
Patent number: 7884106Abstract: A method of stabilizing lipid-rich plaques and method of preventing the rupture thereof, characterized in that an effective amount of 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, its acid adduct salt or a hydrate thereof is administered to patients with lipid-rich plaques. Prevention of plaque rupture and stabilization of plaques can be attained by reducing the occupancy of macrophages in lipid-rich plaques being unstable and tending to rupture among plaques being a lesion from a seat of atherosclerosis and simultaneously increasing the occupancy of collagen therein.Type: GrantFiled: August 19, 2004Date of Patent: February 8, 2011Assignee: Kowa Company, Ltd.Inventors: Kimiyuki Shibuya, Hideyuki Kobayashi, Yasunobu Yoshinaka
-
Publication number: 20110015206Abstract: A method of stabilizing lipid-rich plaques and method of preventing the rupture thereof, characterized in that an effective amount of 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, its acid adduct salt or a hydrate thereof is administered to patients with lipid-rich plaques. Prevention of plaque rupture and stabilization of plaques can be attained by reducing the occupancy of macrophages in lipid-rich plaques being unstable and tending to rupture among plaques being a lesion from a seat of atherosclerosis and simultaneously increasing the occupancy of collagen therein.Type: ApplicationFiled: August 17, 2010Publication date: January 20, 2011Applicant: KOWA CO., LTD.Inventors: Kimiyuki Shibuya, Hideyuki Kobayashi, Yasunobu Yoshinaka
-
Publication number: 20100173938Abstract: The present invention provides a medicament exhibiting an excellent nerve cell death inhibitory action. The present invention relates to a nerve cell death inhibitor comprising a pitavastatin and donepezil or a salt thereof in combination.Type: ApplicationFiled: October 2, 2008Publication date: July 8, 2010Applicant: KOWA COMPANY, LTD.Inventors: Fumiyasu Sato, Yasunobu Yoshinaka, Taro Aoki
-
Publication number: 20090275595Abstract: There is to provide is an agent for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and/or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion comprising an effective amount of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide (hereinafter, referred to as compound 1), its pharmaceutically acceptable salt or a hydrate thereof and Pitavastatin, and a pharmaceutically acceptable carrier, wherein the agent is intended to be simultaneously administered, or separately administered with interval of time to a patient in need thereof.Type: ApplicationFiled: December 9, 2005Publication date: November 5, 2009Applicant: KOWA CO., LTD.Inventors: Hideyuki Kobayashi, Yasunobu Yoshinaka, Kimiyuki Shibuya
-
Publication number: 20070004749Abstract: A method of stabilizing lipid-rich plaques and method of preventing the rupture thereof, characterized in that an effective amount of 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4 -bis(methylthio)-6-methyl-3-pyridyl]acetamide, its acid adduct salt or a hydrate thereof is administered to patients with lipid-rich plaques. Prevention of plaque rupture and stabilization of plaques can be attained by reducing the occupancy of macrophages in lipid-rich plaques being unstable and tending to rupture among plaques being a lesion from a seat of atherosclerosis and simultaneously increasing the occupancy of collagen therein.Type: ApplicationFiled: August 19, 2004Publication date: January 4, 2007Applicant: KOWA CO., LTD.Inventors: Kimiyuki Shibuya, Hideyuki Kobayashi, Yasunobu Yoshinaka